The superstars of precision medicine—EGFR inhibitors in adjuvant treatment of lung cancer

We would like to thank the author of the editorial entitled “EGFR inhibitors in adjuvant treatment of lung cancer—the more specific, the better?” (1) for their interest and comments on our article “Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study” (2).